Health Canada approves Tecentriq (atezolizumab), first new treatment in 20 years for aggressive form of lung cancer

Roche

13 August 2019 - Data show Tecentriq in combination with carboplatin and etoposide helped patients with extensive-stage small cell lung cancer live longer, with a 30% reduction in the risk of death.

Roche Canada announced today that Health Canada has approved Tecentriq (atezolizumab) in combination with carboplatin and etoposide for the first-line treatment of adults with extensive-stage small cell lung cancer (ES-SCLC), representing the first new treatment for the disease in more than two decades. Tecentriq is the first and only approved cancer immunotherapy agent in Canada for first-line small cell lung cancer.

This approval is based on results from the Phase III IMpower133 study, which is the first Phase III study with an immunotherapy-based combination to show improvement in overall survival and progression-free survival in first-line treatment of ES-SCLC.

Read Roche press release

Michael Wonder

Posted by:

Michael Wonder

Posted in:

Cancer , Outcome , Medicine , Canada